Rigel
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
611 Gateway Blvd Ste 900, South San Fran...Phone Number
(650) 624-1100Website
www.rigel.comRevenue
$276.8 MillionStock Symbol
RIGLIndustry
About Rigel
Rigel Pharmaceuticals, Inc. specializes in developing innovative therapies for patients with rare diseases, particularly focusing on chronic immune thrombocytopenia (ITP). Their primary product, TAVALISSE® (fostamatinib disodium hexahydrate), is a spleen tyrosine kinase inhibitor designed for adult patients with thrombocytopenia who have not responded adequately to previous treatments. The company aims to support healthcare providers and patients through comprehensive resources and patient support services. Rigel is committed to improving patient outcomes by offering effective treatment options and ongoing support for managing chronic ITP.Explore more
Rigel Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Rigel
Compare insights from companies similar to Rigel, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Rigel
$276.8M
51-200
Public
$888.4M
1996
JL
Joseph LasagaExecutive Vice President & Chief Business Officer
Rigel Tech Stack
A closer look at the technologies used by Rigel
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Rigel
Sign Up For FreeTo access detailed company insights
Rigel Pharmaceuticals, Inc. specializes in developing innovative therapies for patients with rare diseases, particularly focusing on chronic immune thrombocytopenia (ITP). Their primary product, TAVALISSE® (fostamatinib disodium hexahydrate), is a spleen tyrosine kinase inhibitor designed for adult patients with thrombocytopenia who have not respon... Read More
